Virax Biolabs Group Limited

Equities

VRAX

KYG9495L1251

Biotechnology & Medical Research

Market Closed - Nasdaq 20:59:50 15/07/2024 BST 5-day change 1st Jan Change
1.13 USD 0.00% Intraday chart for Virax Biolabs Group Limited -5.83% -22.60%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Virax Biolabs Group Limited Announces Executive Changes CI
Top Premarket Gainers MT
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 CI
Virax Biolabs Group Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI
Virax Biolabs Group Limited Forges Strategic Research Collaboration with University of Manchester and Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients CI
Top Premarket Gainers MT
Virax Biolabs Group Limited announced that it has received $2.15 million in funding CI
Virax Biolabs Group Limited announced that it expects to receive $2.15 million in funding CI
Virax Biolabs Group Names Nigel McCracken Operating Chief. MT
Virax Biolabs Group Limited Announces Management Changes CI
Certain Ordinary Shares of Virax Biolabs Group Limited are subject to a Lock-Up Agreement Ending on 21-JUL-2023. CI
Virax Biolabs Group Limited Signs Contracts to Launch Two New Research and Laboratory Facilities in the United Kingdom CI
Virax Biolabs Group Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Virax Biolabs Group Limited Auditor Raises 'Going Concern' Doubt CI
Virax Biolabs Group Limited Announces Establishment of Regional Headquarters at Dubai Science Park CI
Virax Biolabs Group Limited Enters into an Agreement for the Distribution of Marburg Virus PCR Testing Kits CI
Virax Biolabs Group Limited announced that it has received $4.000001 million in funding CI
Virax Biolabs Group Limited announced that it expects to receive $4.000001 million in funding CI
Traders Cautious Ahead of Powell Testimony, Stifling US Equity futures MT
Virax Biolabs Signs Agreement to Distribute Avian Influenza A Virus Test Kit in the European Union; Shares Surge Pre-Bell MT
Top Premarket Gainers MT
Virax Biolabs Group Limited Enters into an Agreement for the Distribution of an Avian Influenza A Virus CI
Top Premarket Gainers MT
Cosmos Health Sets First Purchase Order for Virax Biolabs' COVID-19, Influenza Tests MT
Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health CI
Chart Virax Biolabs Group Limited
More charts
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
More about the company

Chiffre d''affaires - Rate of surprise